SRR8518418
— · D
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- D
- subtype
- D
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.590
- IL6_JAK_STAT3_SIGNALING+0.570
- INTERFERON_GAMMA_RESPONSE+0.550
- INFLAMMATORY_RESPONSE+0.420
- TNFA_SIGNALING_VIA_NFKB+0.410
- ALLOGRAFT_REJECTION+0.400
- HEDGEHOG_SIGNALING+0.340
- COMPLEMENT+0.260
- IL2_STAT5_SIGNALING+0.260
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.250
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.390
- UNFOLDED_PROTEIN_RESPONSE-0.320
- MYC_TARGETS_V1-0.290
- FATTY_ACID_METABOLISM-0.250
- SPERMATOGENESIS-0.200
- MTORC1_SIGNALING-0.190
- PEROXISOME-0.160
- ADIPOGENESIS-0.140
- DNA_REPAIR-0.140
- PROTEIN_SECRETION-0.140
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-MP-A4TI-01A-21R-A24X-07 | — | cohortA1 | 0.881 |
| 2 | SRR8518406 | — | D | 0.870 |
| 3 | SRR10842349 | — | — | 0.848 |
| 4 | c7a22797-676e-4f10-a51d-e3ee91a29a21 | — | — | 0.843 |
| 5 | SRR8613765 | — | D | 0.842 |
| 6 | TCGA-OR-A5J8-01 | Adrenocortical Carcinoma | Adrenocortical Carcinoma, Usual Type | 0.834 |
| 7 | SRR8518454 | — | D | 0.832 |
| 8 | 33d6df2f-acc4-4c91-b924-4fb2f519e8ed | — | — | 0.831 |
| 9 | b02dc7a2-3615-4b6c-a3dd-a866d8561d9d | — | — | 0.827 |
| 10 | TCGA-BH-A1F0-01A-11R-A137-07 | — | D | 0.823 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 30 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.590 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.570 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.550 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.420 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.410 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.400 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.340 | Inavolisib | — uncovered |
| COMPLEMENT | 0.260 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.260 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.250 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.240 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.240 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.240 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.230 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.220 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.220 | Inavolisib | — uncovered |
| APOPTOSIS | 0.200 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.170 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.160 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.160 | Temsirolimus | — uncovered |